A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection.
We have completed a phase 1 safety and immunogenicity trial with hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, with MF59 adjuvant as a candidate vaccine. Neutralizing activity to HCV genotype 1a was detected in approximately 25% of the vaccinee sera. In this study, we evaluated vaccinee...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Public Library of Science (PLoS)
2011-01-01
|
| Saila: | PLoS ONE |
| Sarrera elektronikoa: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0023699&type=printable |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|